MedTrace Logo

YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2

NCT07034807 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2025-06-24

No results posted yet for this study

Summary

Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group. The experimental group was given the traditional Chinese medicine prescription ' Shenzhuo Decoction ' ( composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort ) + basic treatment ( including nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, control of other risk factors, etc. ), the control group was given basic treatment, a total of 1 year of drug intervention, followed up for 1 year.

Conditions

  • Diabetic Kidney Disease (DKD)

Interventions

DRUG

the traditional Chinese medicine prescription ' Shenzhuo Decoction '

The traditional Chinese medicine prescription ' Shenzhuo Decoction ' is composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort. It is a traditional Chinese medicine prescription for the treatment of diabetic kidney disease, which was founded by Tong Xiaolin, an academician of the Chinese Academy of Sciences.

COMBINATION_PRODUCT

basic treatment

Basic treatment includes six aspects : nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, and control of other risk factors, which are implemented in accordance with clinical standard treatment specifications.

Sponsors & Collaborators

  • Guang'anmen Hospital，China Academy of Chinese Medical Sciencescancel

    collaborator UNKNOWN

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Tianjin Medical University Chu Hsien-I Memorial Hospital

    collaborator UNKNOWN

  • The Affiliated Hospital to ChangChun University of Chinese Medicinecancel

    collaborator UNKNOWN

  • EFONG PHARMRCEUTICRL

    collaborator UNKNOWN

  • Liu Hongfang

    lead OTHER

Principal Investigators

  • HongFang Liu · Dongzhimen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2028-07-31
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07034807 on ClinicalTrials.gov